NEW YORK BLOOD CENTER, INC.

Headquarter of

266bacf7-7222-ea11-918b-00155d01b4fc

MINNESOTA

View linked company profile

Headquarter of

0f057860-38bd-e911-9179-00155d01b32c

MINNESOTA

View linked company profile

Headquarter of

1316979

KENTUCKY

View linked company profile

Headquarter of

0052899

CONNECTICUT

View linked company profile

WK24BQUAPR13

3YXE1

2025-04-24

COMMUNITY BLOOD CENTER OF GREATER KANSAS

COMMUNITY BLOOD CENTER OF GREATER KANSAS CITY

2024-04-26

2021-02-23

0001079298

2125703009

SC 13G/A

2001-09-10

4

2001-09-10

SC 13G

1999-02-12

8R544

Active

U.S./Canada Manufacturer

2024-05-22

2029-05-22

2025-04-24

CHANNET JUSINO

+1 212-570-3207

1578993325

2020-09-15

View on NPI website

CHRISTOPHER D. HILLYER

PRESIDENT AND CEO

2125703000

333600000X - Pharmacy

Yes

3336S0011X - Specialty Pharmacy

No

+1 516-478-5047

5164785040

549300DB5FEHEJSKOI45

2022-12-01

2023-11-23

LAPSED

FULLY_CORROBORATED

131949477

2023

37

3027378405

View File

2011

316

2125703200

View File

2009

3315

2128351750

View File

2009

3315

2128351750

2009

3315

2128351750

36C24225N0423

View Award on USAspending website

AWARD

DELIVERY ORDER

Department of Veterans Affairs

2025-04-01

34351.50

34351.50

34351.50

BLOOD BANK-BLOOD PRODUCTS AND SUPPLIES

621991: BLOOD AND ORGAN BANKS

6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

36C24225N0431

View Award on USAspending website

AWARD

DELIVERY ORDER

Department of Veterans Affairs

2025-03-15

303749.98

303749.98

303749.98

BLOOD BANK-BLOOD PRODUCTS AND SUPPLIES

621991: BLOOD AND ORGAN BANKS

6506: BLOOD AND BLOOD PRODUCTS

36C24225N0424

View Award on USAspending website

AWARD

DELIVERY ORDER

Department of Veterans Affairs

2025-03-15

177975.04

177975.04

177975.04

BRONX-BLOOD BANK-BLOOD PRODUCTS AND SUPPLIES

621991: BLOOD AND ORGAN BANKS

6515: MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES

2025-03-10

View on USAspending

Department of Health and Human Services

UNDERSTANDING TRANSGENDER WOMEN'S IMMUNE AND BEHAVIORAL RESPONSES TO SEASONAL COVID-19 VACCINES TO IMPROVE THEIR UPTAKE - SEX DIFFERENCES IN IMMUNITY ARE DYNAMIC THROUGHOUT THE LIFESPAN AND CONTRIBUTE TO HETEROGENEITY IN RISK OF INFECTIOUS DISEASES AND RESPONSE TO VACCINATION. SEXUAL DIMORPHISM IS, IN PART, DRIVEN BY SEX HORMONES AND HAS BEEN DEMONSTRATED IN BOTH INNATE AND ADAPTIVE IMMUNITY; TESTOSTERONE HAS AN IMMUNOSUPPRESSIVE EFFECT WHILE ESTROGEN IS IMMUNOENHANCING. THUS, FEMALES TEND TO MOUNT STRONGER IMMUNE RESPONSES, EXHIBIT LOWER INFECTION RATES FOR A VARIETY OF PATHOGENS, AND DEMONSTRATE ELEVATED RESPONSES TO VACCINATION. HOWEVER, THE MOLECULAR MECHANISMS DRIVING ENHANCED IMMUNITY IN FEMALES ARE NOT WELL UNDERSTOOD, AND THE DEGREE TO WHICH EXOGENOUS SEX HORMONES CONTRIBUTE TO IMMUNE RESPONSE IS UNKNOWN. TO DISSECT THE ROLE OF FEMALE SEX HORMONES IN ENHANCED IMMUNITY AND TO BROADEN OUR UNDERSTANDING OF SEXUAL DIMORPHISM IN IMMUNITY AND HEALTH, WE PROPOSE TO STUDY THE IMMUNE RESPONSES OF ADULT TRANSGENDER WOMEN (TW, INDIVIDUALS WHO IDENTIFY AS WOMEN BUT WERE ASSIGNED MALE AT BIRTH) UNDERGOING GENDER-AFFIRMING HORMONE THERAPY (GAHT). THIS WILL PROVIDE A UNIQUE OPPORTUNITY TO UNDERSTAND THE IMPACT OF SEX HORMONES ON THE IMMUNE SYSTEM GENERALLY, AND MORE SPECIFICALLY, IN RESPONSE TO THE UPDATED SEASONAL COVID-19 VACCINES. NO STUDIES HAVE EXAMINED INTERACTIONS BETWEEN COVID-19 VACCINES AND GAHT. WE HYPOTHESIZE THAT TW UNDERGOING FEMINIZING GAHT WILL DEVELOP ENHANCED IMMUNE RESPONSES THAT ALIGN MORE WITH THEIR GENDER IDENTITY THAN THEIR BIOLOGICAL SEX. UPTAKE OF THE 2023-24 SEASONAL COVID-19 VACCINE IS CURRENTLY LOW IN TRANSGENDER PEOPLE (12.5%), WHICH IS PROBLEMATIC SINCE THEY ARE MORE LIKELY TO BECOME SEVERELY ILL, DIE, OR INCUR COVID-RELATED SOCIAL HARMS (E.G., VIOLENCE, JOB LOSS) IF INFECTED, HOWEVER, 63% ARE OPEN TO IT. UNTANGLING THE RELATIONSHIP BETWEEN IMMUNE RESPONSE AND GENDER IN TW MAY FACILITATE AND IMPROVE EVIDENCE-BASED UPTAKE OF THE SEASONAL COVID-19 VACCINES IN THIS POPULATION. EVIDENCE FROM OTHER FIELDS (E.G., HIV) SHOWS THAT TW ARE UNLIKELY TO USE BIOMEDICAL PRODUCTS (INCLUDING VACCINES) UNLESS THERE EXIST BIOMEDICAL AND BEHAVIORAL DATA SPECIFIC TO THIS POPULATION. HOWEVER, TO FACILITATE UPTAKE AND A SUSTAINED USE IN TW OF THE COVID-19 VACCINES OFFERED, WE MUST UNDERSTAND NOT ONLY THEIR IMMUNOLOGICAL RESPONSE PROFILE, BUT ALSO THEIR BARRIERS, FACILITATORS, AND MOTIVATORS TO USE. IN AIM 1, HUMORAL AND CELLULAR RESPONSES IN ADULT TW (21-49 YEARS) BEFORE AND AFTER IMMUNIZATION WITH THE UPDATED SEASONAL COVID-19 VACCINE, WHEN OFFERED, WILL BE COMPARED TO THOSE ELICITED IN CLINICALLY- AND AGE-MATCHED CISGENDER MEN AND WOMEN WITH SIMILAR COVID-19 VACCINE UPTAKE AND PRIOR INFECTIONS HISTORIES, AND WHO ARE PLANNING TO RECEIVE THE UPDATED VACCINE AND BE BLED PRIOR TO IMMUNIZATION (BASELINE) FOLLOWED BY THREE BLEEDS 7-, 28- AND 180-DAYS POST VACCINATION. IN AIM 2, WE WILL USE THE COM-B MODEL AND ENGAGE THE TW IN SURVEYS, INTERVIEWS, AND IN AN INTERVENTION DEVELOPMENT WORK GROUP BEFORE WE DEVELOP A DRAFT INTERVENTION (“OPTIMIZEVAX”) TO FACILITATE UPDATED SEASONAL COVID-19 VACCINE UPTAKE. TOGETHER, THE AIMS COMPRISE A CRITICAL FIRST STEP TOWARDS DETERMINING IF GAHT HAS IMMUNOENHANCING EFFECTS, AND A FOUNDATION HOW TO FACILITATE COVID-19 VACCINES UPTAKE BY TW.

267121.00

0.00

0.00

2024-12-13

View on USAspending

Department of Health and Human Services

DESIGNING A ROBUST PLATFORM FOR THE IN VITRO PROPAGATION OF BABESIA MICROTI IN HUMAN RBCS - THE OVERALL GOAL OF THE R61 PHASE OF OUR PROPOSAL IS TO ESTABLISH A CONTINUOUS IN VITRO CULTURE SYSTEM OF B. MICROTI IN HUMAN RBCS TO ENABLE A PLATFORM AMENABLE FOR FUTURE EXPERIMENTAL INVESTIGATION, SPECIFICALLY THE IDENTIFICATION AND CHARACTERIZATION OF HUMAN RBC RECEPTOR-B. MICROTI LIGAND INTERACTIONS THAT FACILITATE PARASITE INVASION WHICH WILL BE EXPLORED IN THE R33 PHASE. WE HYPOTHESIZE THAT B. MICROTI LIKE OTHER ERYTHROCYTE SEEKING PROTOZOANS HAVE PREFERENTIAL CELLULAR INVASION AND PROLIFERATION NEEDS. TO ESTABLISH IF THIS IS TRUE, WE WILL IN THE R61 PHASE, MILESTONE1, ANALYZE THE PARASITE-HOSTING CAPABILITIES OF SUB-POPULATIONS OF RBCS USING SEPARATION AND PURIFICATION PROTOCOLS FROM PERIPHERAL BLOOD, UMBILICAL CORD BLOOD AND HEMOCHROMATOSIS BLOOD DRAWS, USING PARASITE INOCULUM FROM BOTH B. MICROTI INFECTED MICE AND INFECTED HUMAN SOURCES. WE WILL ALSO ANALYZE PURE POPULATIONS FROM ERYTHROID PROGENITOR CELLS THAT HAVE BEEN FACS SORTED FOR THE ABILITY TO BE INFECTED WITH B. MICROTI. ONCE A SPECIFIC HOST RBC HAS BEEN IDENTIFIED ALONG WITH THE INOCULUM, WE WILL ASSAY CULTURE MEDIA ALONG WITH SERUM/LIPID ADDITIVES AND VITAMIN/MINERAL ADDITIVES, AND IDEAL GAS CONDITIONS, TO ACHIEVE MILESTONE 2. WORKING WITH THE HIGHEST INFECTION ACHIEVING MEDIA, HOST RBC AND PARASITE SOURCE, WE WILL MONITOR PARASITE EGRESS AND RE-INVASION AFTER ENSURING ADEQUATE HOST RBCS THAT THE PARASITE REQUIRES, IN CULTURE, IN MILESTONE 3. FACS AND GIEMSA ESTIMATION OF PARASITEMIA AND OVERALL CULTURE DYNAMICS WILL BE CONSTANTLY MONITORED, PAYING PARTICULAR ATTENTION TO SUB-POPULATION STRUCTURE OF THE CULTURES, WHICH WILL INFORM US OF SUCCESS OF VARIOUS MILESTONES. AS PART OF MILESTONE 4, WE WILL CRYOPRESERVE AND REVIVE STOCKS OF CULTURE-ADAPTED PARASITES. COMPREHENSIVE BIO-PROTOCOLS WILL BE WRITTEN UP DETAILING SPECIFIC ASPECTS OF EACH STEP IN THE CULTURING PROCESS. ONCE AN IN VITRO CULTURE SYSTEM IS IN PLACE CRITICAL ASPECTS OF HUMAN HOST-PARASITE RELATIONSHIPS CAN BE EXPLORED AND WE WILL INVESTIGATE B. MICROTI INVASION OF THE HUMAN RBC, IN THE R33 PHASE. TO IDENTIFY AND CHARACTERIZE RBC SURFACE MOLECULES THAT FUNCTION IN INVASION, WE WILL USE ENZYMATICALLY TREATED RBCS, CLINICALLY DEFINED RBCS DEFICIENT IN SPECIFIC RECEPTOR, INHIBITION OF INVASION ASSAYS USING ANTIBODIES/PEPTIDES AND FORWARD GENETIC APPROACHES USING SHRNA MEDIATED KNOCKDOWN OF SPECIFIC RBC RECEPTORS. COGNATE B. MICROTI LIGANDS WILL THEN BE IDENTIFIED USING GEL OVERLAY AND PULL-DOWN ASSAYS. VALIDATION OF THESE RECEPTOR-LIGAND INTERACTIONS WILL BE CARRIED OUT VIA AVEXIS AND BIACORE ASSAYS. FUNCTIONAL VALIDATION ASSAYS WILL INCLUDE INHIBITION OF INVASION ASSAYS WITH ANTI-LIGAND ANTIBODIES AND RECOMBINANT LIGAND PROTEINS. WE BELIEVE THAT THESE INNOVATIVE APPROACHES WILL GREATLY ENHANCE THE OPPORTUNITIES AND CAPABILITIES FOR INVESTIGATIONS INTO B. MICROTI BIOLOGY.

427000.00

0.00

0.00

2024-12-13

View on USAspending

Department of Health and Human Services

STRUCTURAL AND FUNCTIONAL ALTERATION OF HOST RBCS BY BABESIA - BABESIA SPP., THE ETIOLOGIC AGENTS OF BABESIOSIS IN ANIMALS AND HUMANS, ARE INTRAERYTHROCYTIC PROTOZOAN PARASITES TRANSMITTED TO HOSTS BY IXODES TICKS. LONG KNOWN TO CAUSE DISEASE IN DOMESTIC ANIMALS, B. MICROTI AND B. DIVERGENS HAVE EMERGED AS A GROWING PUBLIC HEALTH CONCERN FOR HUMANS, CAUSING FULMINANT DISEASE IN IMMUNO- COMPROMISED AND ASPLENIC POPULATIONS AND AN ALARMINGLY HIGH RATE OF HOSPITALIZATIONS AND SOMETIMES FATALITY IN THESE INDIVIDUALS. MOST CLINICAL COMPLICATIONS ARE DUE TO THE ABILITY OF THE PARASITES TO STRIKINGLY ALTER PROPERTIES OF HOST RBCS. I HYPOTHESIZE THAT STRUCTURAL, MORPHOLOGICAL, RHEOLOGICAL, AND FUNCTIONAL CHANGES OCCURRING IN INFECTED RBCS (IRBCS) ARE THE RESULT OF THE EXPORT OF SPECIFIC BABESIA PROTEINS, INCLUDING PROTEASES, WHICH INTERACT WITH THE CYTOPLASMIC, MEMBRANE SKELETAL AND MEMBRANE COMPONENTS OF THE RBCS. THE OVERARCHING GOAL OF THIS PROPOSAL IS TO ELUCIDATE THE ALTERATIONS TO THE HOST RBCS AND UNCOVER THE MECHANISMS UNDERLYING THESE CHANGES BY IDENTIFYING AND CHARACTERIZING THE MOLECULAR PLAYERS-BOTH IMPACTED RBC CYTOSKELETAL PROTEINS AND THE KEY PARASITE MOLECULES RESPONSIBLE FOR THE CHANGES, TO BUILD A COMPREHENSIVE PICTURE OF HOST RBC REMODELING DURING INFECTION. AIM 1 WILL CONDUCT MORPHOLOGICAL, RHEOLOGICAL, AND BIOPHYSICAL ANALYSES TO DEFINE ALTERATIONS OF IRBCS USING IMAGE FLOW CYTOMETRY ALONG WITH MACHINE LEARNING ANALYSIS, EKTACYTOMETRY AND STIMULATED EMISSION DEPLETION MICROSCOPY. CHANGES IN 5 KEY RBC CYTOSKELETAL PROTEINS ON INFECTION-BAND 3, SPECTRIN, ANKYRIN, PROTEINS 4.1 AND 4.2, WILL BE MAPPED. SPECIFIC ANTIBODIES WILL BE USED IN IMMUNO-CHEMICAL METHODS TO TRACK CHANGES IN THESE CYTOSKELETAL ELEMENTS UP ON INFECTION AND MASS SPECTROMETRY PERFORMED TO IDENTIFY SPECIFIC PHOSPHORYLATION AND CLEAVAGE MODIFICATIONS. AIM 2 WILL IDENTIFY AND CHARACTERIZE 2 PARASITE CYSTEINE PROTEASES AND 2 ASPARTIC PROTEASES INCLUDING THEIR PROCESSING, SUB-CELLULAR LOCALIZATION, IDENTIFICATION OF EXPORT SEQUENCE SIGNATURES AND DEVELOP MOLECULAR TOOLS FOR DOWNSTREAM FUNCTIONAL ANALYSIS. THE SPECIFIC INTERACTIONS OF THESE PROTEASES WITH THE HOST RBC CYTOSKELETON PROTEINS WILL BE STUDIED USING INSIDE-OUT RBC VESICLE ASSAYS, IMMUNOPRECIPITATION, AND SURFACE PLASMON RESONANCE TO IDENTIFY SPECIFIC INTERACTIONS AND DELINEATE THE DOMAINS REQUIRED FOR MODIFICATION OF HOST CYTOSKELETAL PROTEINS. OVERALL, THESE AIMS WILL PROVIDE INSIGHTS INTO MECHANISMS OF RBC REMODELING BY THE PARASITE AND ITS PHYSIOLOGICAL RELEVANCE IN BABESIOSIS, OPENING DOORS FOR NOVEL AND TARGETED CHEMOTHERAPEUTICS, IN LINE WITH NIAID’S MISSION TO TACKLE EMERGING DISEASES RELEVANT TO PUBLIC HEALTH. A COMPREHENSIVE MENTORSHIP TEAM (DRS. LOBO, NARLA, HILLYER, YAZDANBAKHSH, MONTERO, ALLRED, MONETTI AND NORTH) HAS BEEN ASSEMBLED TO ENSURE THAT BOTH SCIENTIFIC AND CAREER DEVELOPMENT GOALS ARE MET. THE IMMEDIATE GOAL IS TO GAIN ADVANCED TRAINING IN A RELATIVELY UNDERSTUDIED PARASITE USING MULTIPRONGED EXPERIMENTAL APPROACHES, ALONG WITH ACQUIRING SOFT SKILLS NEEDED FOR SCIENTIFIC INDEPENDENCE. THIS K99/R00 GRANT WOULD EVENTUALLY PROVIDE DATA AND MOLECULAR TOOLS FOR R01-LEVEL FUNDING, FULFILLING LONG-TERM CAREER GOALS FOR LAUNCHING AN INDEPENDENT CAREER IN STUDYING HOST-PARASITE INTERACTION IN BABESIOSIS.

134730.00

0.00

0.00

2024-08-29

View on USAspending

Department of Health and Human Services

IMPACT OF GEOGRAPHIC MOBILITY ON PREP AND HIV CARE OUTCOMES AMONG LATINO GAY, BISEXUAL AND OTHER MEN WHO HAVE SEX WITH MEN - ABSTRACT HIV CONTINUES TO BE A MAJOR PUBLIC HEALTH CONCERN FOR HISPANIC/LATINO GAY, BISEXUAL AND OTHER MEN WHO HAVE SEX WITH MEN (GBMSM) IN THE U.S. IMMIGRANT/MIGRANT LATINO GBMSM MAKE UP THE LARGEST PROPORTION OF FOREIGN-BORN SEXUAL MINORITY POPULATION AND ARE A KEY GROUP VULNERABLE TO HIV ACQUISITION AND TRANSMISSION, YET ARE RARELY THE FOCUS OF FUNDED RESEARCH. IMMIGRANT/MIGRANT LATINO GBMSM ARE MORE LIKELY TO RECEIVE DELAYED HIV DIAGNOSES AND TO BE UNINSURED/UNDERINSURED THAN U.S.-BORN LATINOS, IN ADDITION TO FACING IMMIGRATION- RELATED BARRIERS TO CARE. SPATIAL SEGREGATION AMONG IMMIGRANT/MIGRANT LATINO GBMSM IS LINKED TO DIMINISHED PROXIMITY TO SPANISH-LANGUAGE PRE-EXPOSURE PROPHYLAXIS (PREP) AND HIV SERVICE NAVIGATION SERVICES AND REDUCED ACCESS TO CULTURALLY COMPETENT PREP AND HIV CARE, CREATING AN INCREASINGLY INVISIBLE HIV BURDEN. RATES OF NEW HIV DIAGNOSES AND HIV VIRAL SUPPRESSION VARY DRAMATICALLY BETWEEN COUNTRIES OF ORIGIN FOR IMMIGRANT/MIGRANT LATINO GBMSM. GEOGRAPHIC MOBILITY HAS BEEN SHOWN TO ENHANCE HIV VULNERABILITY AND ADVERSELY IMPACT HIV CARE AND TREATMENT IN PEOPLE LIVING WITH HIV, YET THERE IS LIMITED DATA ON HOW GEOGRAPHIC MOBILITY IMPACTS PREP AND HIV CARE OUTCOMES AMONG LATINO GBMSM IN THE U.S. FURTHER, GEOGRAPHIC MOBILITY MAY LEAD TO POSITIVE OUTCOMES, AS PEOPLE MAY TRAVEL FOR BETTER ACCESS TO HIV PREVENTION AND CARE SERVICES, OR MOVE TOWARD BETTER SUPPORT NETWORKS OR AWAY FROM HIV AND PREP STIGMA PREVALENT IN THEIR COMMUNITIES. TO ADDRESS THE KNOWLEDGE GAP REGARDING THE IMPACT OF GEOGRAPHIC MOBILITY FOR LATINO GBMSM ON PREP AND HIV CARE OUTCOMES AND TO INFORM FUTURE INTERVENTIONS, THE SPECIFIC AIMS FOR THIS EXPLORATORY PROPOSAL ARE: AIM 1: TO CHARACTERIZE PATTERNS OF GEOGRAPHIC MOBILITY IN THE PAST 3 YEARS, INCLUDING DESTINATIONS, TEMPORALITY (INCLUDING DURATION, FREQUENCY, OR SEASONALITY), PURPOSE, AND LEVEL OF PLANNING OVER TRAVEL AMONG 40 LATINO GBMSM NOT LIVING WITH HIV (ON/NOT ON PREP) AND 40 LATINO GBMSM LIVING WITH HIV (ON/NOT ON ART) IN NYC USING QUALITATIVE IN-DEPTH INTERVIEWS AND MOBILITY MAPS. AIM 2: TO DETERMINE HOW PAST-YEAR GEOGRAPHIC MOBILITY IMPACTS PREP CARE OUTCOMES (PREP INITIATION/ADHERENCE, RETENTION AND PERSISTENCE IN PREP CARE) AND HIV CARE OUTCOMES (ART INITIATION/ADHERENCE, RETENTION IN CARE, AND VIRAL SUPPRESSION) LONGITUDINALLY OVER 12 MONTHS. WE WILL ENSURE A RANGE OF LATINO GBMSM EXPERIENCES ARE INCLUDED, BY PURPOSIVE SAMPLING BY: LIVING WITH AND WITHOUT HIV, REGION OF BIRTH (DOMINICAN REPUBLIC, PUERTO RICO, MEXICO/CENTRAL AMERICA, AND SOUTH AMERICA), AND RECENT VS. NON-RECENT IMMIGRANT/MIGRANT TO THE U.S. OUR APPROACH IS INNOVATIVE, AS IT EXAMINES THE IMPACT OF GEOGRAPHIC MOBILITY ON PREP AND HIV CARE OUTCOMES AMONG LATINO GBMSM WHO HAVE BEEN DISPROPORTIONATELY AFFECTED BY HIV AND HAVE BEEN UNDERSTUDIED, APPLIES MOBILITY MAPS IN A NOVEL WAY, AND HAS POTENTIAL TO INFORM FUTURE DESIGN OF INTERVENTIONS TO IMPROVE PREP AND HIV CARE OUTCOMES IN THIS POPULATION.

308371.00

0.00

0.00

2024-08-21

View on USAspending

Department of Health and Human Services

EVALUATING ACCESSORY CELLS TO IMPROVE HOMING AND ENGRAFTMENT EFFICIENCY OF CD34+ CELLS FROM SICKLE CELL DISEASE PATIENTS - AS A CURE FOR THE LIFE-THREATENING HEMOGLOBINOPATHY OF SICKLE CELL DISEASE (SCD), GENE THERAPY HAS IMMENSE POTENTIAL, AVOIDING THE BURDENS WITH ALLOGENEIC TRANSPLANT OF FINDING AN APPROPRIATE DONOR AND THE RISK OF GRAFT VERSUS HOST DISEASE. COLLECTING AN ADEQUATE NUMBER OF HEMATOPOIETIC STEM CELLS (HSCS) FOR GENE MODIFICATION, HOWEVER, OFTEN REQUIRES AT LEAST 2 DAYS AND SOMETIMES MULTIPLE CYCLES OF LEUKAPHERESIS, IMPOSING A COST AND LOGISTICAL BURDEN. CHEMOTHERAPY CONDITIONING PRIOR TO INFUSION OF THE MODIFIED HSCS IS MYELOABLATIVE WITH WEEKS UNTIL NEUTROPHIL, LYMPHOID, AND PLATELET RECOVERY, IMPOSING INFECTIOUS AND TRANSFUSION-RELATED RISKS. THESE ISSUES ARE SIGNIFICANT QUALITY OF LIFE CONCERNS IN THE UNITED STATES, WHERE ABOUT 100,000 PEOPLE LIVE WITH SCD, AND ARE LIKELY TO LIMIT ACCESS TO SCD GENE THERAPY TO HIGHLY EXPERIENCED TRANSPLANT CENTERS. IN LOWER AND MIDDLE INCOME COUNTRIES SUCH AS IN SUB-SAHARAN AFRICA, WHERE ABOUT 236,000 BABIES ARE BORN EACH YEAR WITH SCD, HOWEVER, THESE ISSUES MAY BE INSURMOUNTABLE BARRIERS TO SCD GENE THERAPY IMPLEMENTATION. THIS PROPOSAL AIMS TO ADDRESS THESE IMPEDIMENTS TO EQUITY OF ACCESS TO SCD GENE THERAPY BY EVALUATING A LIKELY-TO-BE COST-EFFECTIVE AND EASY METHOD TO INCREASE HSC HOMING AND ENGRAFTMENT. IN THE NON-SCD AUTOLOGOUS TRANSPLANT SETTING, THE FLOW-THROUGH FRACTION AFTER CD34+ HSC IMMUNOMAGNETIC SELECTION IS KNOWN TO CONTAIN ACCESSORY/IMMUNE CELLS ASSOCIATED WITH IMPROVED HSC HOMING AND ENGRAFTMENT. WE HYPOTHESIZE THAT, IN THE SCD AUTOLOGOUS TRANSPLANT SETTING, CO-INFUSING WITH THE CD34+ CELLS PART OF THE CD34-NEGATIVE FRACTION, WHICH IS NORMALLY DISCARDED AFTER IMMUNOMAGNETIC CD34+ CELL SELECTION, WILL ASSIST WITH HSC HOMING AND ENGRAFTMENT. USING THE IMMUNE AND ACCESSORY CELLS LEFT OVER FROM CD34+ CELL SELECTION OF SCD CORD BLOOD UNITS AND SCD PLERIXAFOR-MOBILIZED APHERESIS PRODUCTS, WE WILL IMMUNOPHENOTYPE THE ACCESSORY FRACTION AND DETERMINE IN VITRO HOMING EFFICIENCY OF A PRODUCT’S CD34+ CELLS INCUBATED ALONE (CONTROL ARM) AND WITH (EXPERIMENTAL ARM) ITS FLOW THROUGH CELLS (AIM 1). WE WILL ALSO PERFORM TRANSPLANT STUDIES IN IMMUNODEFICIENT MICE WITH CD34+ CELLS ALONE (CONTROL ARM) AND WITH (EXPERIMENTAL ARM) ITS FLOW THROUGH CELLS TO LOOK FOR IMPROVEMENT IN HUMAN CELL ENGRAFTMENT (AIM 2). ALTOGETHER, WE BELIEVE THAT EVALUATING THE EFFECTIVENESS OF ADDING BACK THE CD34- FLOW THROUGH AFTER CD34+ GENE MODIFICATION MAY OFFER A COST-EFFECTIVE METHOD FOR INCREASING EQUITY OF ACCESS TO SCD GENE THERAPY.

128100.00

0.00

0.00

2009-06-23

Complaint

525 EXECUTIVE BOULEVARD, ELMSFORD, NY, 10523

Health

Partial

View Inspection data on OSHA website

1980-08-11

Complaint

155 DURGEA ROAD, Melville, NY, 11747

Safety

Partial

View Inspection data on OSHA website

13-1949477

% GAIL SHAYO

Government Instrumentality, Title-Holding Corporation, Charitable Organization, Educational Organization, Local Association of Employees, Agricultural Organization, Horticultural Organization, Board of Trade, Business League, Pleasure, Recreational, or Social Club, Fraternal Beneficiary Society, Order or Association, Voluntary Employees' Beneficiary Association (Non-Govt. Emps.), Voluntary Employees' Beneficiary Association (Govt. Emps.), Domestic Fraternal Societies and Associations, Teachers Retirement Fund Assoc., Benevolent Life Insurance Assoc., Mutual Ditch or Irrigation Co., Burial Association, Cemetery Company, Credit Union, Other Mutual Corp. or Assoc., Mutual Insurance Company or Assoc. Other Than Life or Marine, Corp. Financing Crop Operations, Supplemental Unemployment Compensation Trust or Plan, Employee Funded Pension Trust (Created Before 6/25/59), Post or Organization of War Veterans, Legal Service Organization, Black Lung Trust, Multiemployer Pension Plan, Veterans Assoc. Formed Prior to 1880, Trust Described in Sect. 4049 of ERISA, Title Holding Co. for Pensions, etc., State-Sponsored High Risk Health Insurance Organizations, State-Sponsored Workers' Compensation Reinsurance, ACA 1322 Qualified Nonprofit Health Insurance Issuers, Apostolic and Religious Org. (501(d)), Cooperative Hospital Service Organization (501(e)), Cooperative Service Organization of Operating Educational Organization (501(f)), Child Care Organization (501(k)), Charitable Risk Pool, Qualified State-Sponsored Tuition Program, 4947(a)(1) - Private Foundation (Form 990PF Filer)

1961-02

Type of organization and use of contribution: A public charity. Deductibility Limitation: 50% (60% for cash contributions)

Interstate

(732) 668-5042

(212) 699-5165

DSHAH@NYBC.ORG

2006-05-24

Private(Property)

77

279

14

View on FMCSA website

2016-10-18

Terminated

no monetary award

Both plaintiff and defendant demand jury

Other Contract Actions

NEW YORK BLOOD CENTER, INC.

Plaintiff

NATIONAL MARROW DONOR PROGRAM

Defendant

2016-02-23

Terminated

no monetary award

Plaintiff demands jury

Americans with Disabilities Act - Employment

NUNEZ

Plaintiff

NEW YORK BLOOD CENTER, INC.

Defendant

2012-10-23

Terminated

no monetary award

Plaintiff demands jury

Civil Rights Employment

NEW YORK BLOOD CENTER, INC.

Defendant

GITTO

Plaintiff